Samita Garg, Abstract Co-Author: Nothing to Disclose

Nizar Zein, Abstract Co-Author: Nothing to Disclose

Kavita Garg MD, Presenter: Nothing to Disclose

Nonalcoholic fatty liver disease (NAFLD) is an important public health concern and a risk factor for cardiac disease, diabetes and cancer. Though patients with hepatic steatosis can be asymptomatic for years, a subset will progress to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatoma. NAFLD includes a spectrum of histopathological changes ranging from simple steatosis to NASH to cirrhosis. Liver biopsy is considered a gold standard, however, ultrasound, CT and MR can be used to diagnose NAFLD noninvasively. Other diffuse hepatocellular diseases such as Hepatitis C, hemochromatosis, A1-antitrypsin can confound imaging findings. Emerging quantitative assessment methods such as elastography and MR appear promising, however prospective studies are warranted for validation.  

Prevalence and histopathologic activity scores of NAFLD Typical, atypical findings and differential diagnosis of NAFLD on ultrasound, CT and MR. Pros and cons of different imaging modalities in NAFLD screening. Clinical associations of NAFLD including for liver transplant, gastric bypass surgery, chemotherapy, pancreatic fat and body composition are briefly discussed. Emerging quantitative assessment methods such as MR and elastography.  

http://abstract.rsna.org/uploads/2014/14004170/14004170_k8qc.pdf

Garg, S, Zein, N, Garg, K, About Time to Pay Closer Attention to Nonalcoholic Fatty Liver Disease and the Role of Imaging.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14004170.html